Table 1 Study population characteristics
Parameter | Study group n (%) / mean ± SD / median [IQR] |
|---|---|
Total number of patients: | N = 99 |
Age (years) | 75.0 [66.0–81.5] |
Female | 35 (35.4) |
Weight (kg) | 80.0 [67.0–87.8] |
Body mass index (kg/m2) | 26.5 [24.2–30.2] |
Body surface area (m2) | 1.89 ± 0.25 |
Comorbidities: | |
HF with preserved ejection fraction | 32 (32.3) |
HF with reduced ejection fraction | 44 (44.4) |
Right ventricular HF | 25 (25.3) |
Dilated cardiomyopathy | 36 (36.4) |
Arterial hypertension | 64 (64.6) |
Diabetes | 32 (32.3) |
Chronic kidney disease | 46 (46.5) |
stage I – II | 60 (60.6) |
stage III - IV | 39 (39.4) |
Atrial fibrillation | 39 (63.9) |
Osteoarthritis | 24 (24.2) |
Distance in 6-min walking test (m): | 150.0 [40.0–440.0] |
Pharmacotherapy: | |
Beta-blockers | 85 (87.6) |
ACEi | 78 (80.4) |
ARBs | 11 (11.3) |
Ca channel antagonists | 20 (20.6) |
Diuretics | 76 (78.4) |
Mineralocorticoid receptor antagonists | 35 (36.1) |